BiotechTube

KT-413

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non Hodgkin Lymphoma

Conditions

Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, DLBCL, MYD88 Gene Mutation

Trial Timeline

Jun 13, 2022 → Jul 28, 2023

NCT ID
NCT05233033

About KT-413

KT-413 is a phase 1 stage product being developed by Kymera Therapeutics for Non Hodgkin Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05233033. Target conditions include Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, DLBCL.

What happened to similar drugs?

1 of 20 similar drugs in Non Hodgkin Lymphoma were approved

Approved (1) Terminated (2) Active (17)
❌Nivolumab + Brentuximab vedotinOno PharmaceuticalPhase 3
🔄R-mabHDI and ABVD + ABVDEli LillyPhase 3
🔄enzastaurin + placeboEli LillyPhase 3
🔄Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
🔄Camrelizumab + Investigator's choice of ChemotherapyJiangsu Hengrui MedicinePhase 3
🔄pembrolizumab + brentuximab vedotinMerckPhase 3
🔄Zoledronic Acid + Vitamin D + Calcium CarbonateNovartisPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05233033Phase 1Completed

Competing Products

20 competing products in Non Hodgkin Lymphoma

See all competitors
ProductCompanyStageHype Score
AFM13AffimedPhase 2
25
VIP152 + BTKiVincerx PharmaPhase 1
11
PLX3397Daiichi SankyoPhase 2
35
YM155 + RituximabAstellas PharmaPhase 2
35
TazemetostatEisaiPhase 2
35
ONTAKEisaiPhase 2
35
TazemetostatEisaiPhase 1
29
ME-401Kyowa KirinPhase 1
29
ME-401Kyowa KirinPhase 2
39
TirabrutinibOno PharmaceuticalPhase 1
29
ONO-7018Ono PharmaceuticalPhase 1
33
Nivolumab + Brentuximab vedotinOno PharmaceuticalPhase 3
32
ONO-7018 + ONO-7018Ono PharmaceuticalPhase 1
33
R-mabHDI and ABVD + ABVDEli LillyPhase 3
36
Prednisone + Vinblastine + Doxorubicin (Adriamycin) + GemcitabineEli LillyPhase 1/2
32
gemcitabineEli LillyPhase 2
27
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
35
LY4152199 - IVEli LillyPhase 1
36
R-mabHD + ABVDEli LillyPhase 2
31
enzastaurin + placeboEli LillyPhase 3
40